{"filing":{"accession_number":"0001654954-26-007992","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"a6788s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007992/a6788s.htm"},"events":[{"id":30787,"run_id":28227,"accession_number":"0001654954-26-007992","anchor_item_number":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"AstraZeneca announces admission to trading of €2.55 billion in debt securities across four series (€700M, €600M, €500M, and €750M notes) with maturities ranging from 2030 to 2038, issued by its wholly owned subsidiary AstraZeneca Finance LLC and admitted to the London Stock Exchange Main Market on 1 September 2026. This constitutes creation of a material direct financial obligation and is a significant capital-raising event.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":33497,"accession_number":"0001654954-26-007992","item_number":null,"item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AstraZeneca announces admission to trading of €2.55 billion in debt securities across four series (€700M, €600M, €500M, and €750M notes) with maturities ranging from 2030 to 2038, issued by its wholly owned subsidiary AstraZeneca Finance LLC and admitted to the London Stock Exchange Main Market on 1 September 2026. This constitutes creation of a material direct financial obligation and is a significant capital-raising event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:37:36.572952+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-01"}]}